| MeSH term | MeSH ID | Detail |
|---|---|---|
| Malacoplakia | D008287 | 1 associated lipids |
| Myoclonic Cerebellar Dyssynergia | D002527 | 1 associated lipids |
| Lichen Nitidus | D017513 | 1 associated lipids |
| Feline Infectious Peritonitis | D016766 | 1 associated lipids |
| Meningitis, Cryptococcal | D016919 | 1 associated lipids |
| Oculomotor Nerve Diseases | D015840 | 1 associated lipids |
| Cutis Laxa | D003483 | 1 associated lipids |
| Invasive Pulmonary Aspergillosis | D055744 | 1 associated lipids |
| Intestinal Volvulus | D045822 | 1 associated lipids |
| Hand Injuries | D006230 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Walpoth B et al. | Prevention of cardiac allograft rejection by FK506 and rapamycin: assessment by histology and nuclear magnetic resonance. | 1992 | Transpl. Int. | pmid:14621877 |
| Furukawa H et al. | The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs. | 1992 | Transplantation | pmid:1373531 |
| Hasegawa S et al. | Combination use of suboptimal dose of FK 506 and cyclosporine in canine lung transplantation. | 1992 | J. Thorac. Cardiovasc. Surg. | pmid:1279319 |
| Mochizuki M | [Immunotherapy in ocular diseases]. | 1992 | Nippon Ganka Gakkai Zasshi | pmid:1283052 |
| Lee TK et al. | Mucosal glutamine utilization after small-bowel transplantation: an electrophysiologic study. | 1992 | J. Surg. Res. | pmid:1382152 |
| Petros AM et al. | NMR studies of an FK-506 analog, [U-13C]ascomycin, bound to FK-506-binding protein. | 1992 | J. Med. Chem. | pmid:1377749 |
| Mizuno K et al. | Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine. | 1992 Jan-Feb | Anticancer Res. | pmid:1373592 |
| Arai S et al. | The impact of FK506 on graft coronary disease of rat cardiac allograft--a comparison with cyclosporine. | 1992 Jul-Aug | J. Heart Lung Transplant. | pmid:1379829 |
| Fagiuoli S et al. | FK 506: a new immunosuppressive agent for organ transplantation. Pharmacology, mechanism of action and clinical applications. | 1992 Jul-Aug | Ital J Gastroenterol | pmid:1381245 |
| Tong J et al. | Effect of FK-506 and cyclosporin A on in vitro CFU-GM growth in severe aplastic anemia patients. | 1992 Jul-Aug | Haematologica | pmid:1385279 |
| Nazer H et al. | FK 506 associated disorders in liver transplantation. | 1992 May-Jun | J. Gastroenterol. Hepatol. | pmid:1377038 |
| Bowman H and Lennard TW | Immunosuppressive drugs. | 1992 Nov 4-17 | Br J Hosp Med | pmid:1282440 |
| Sattler M et al. | Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. | 1992 Sep-Oct | Drug Metab. Dispos. | pmid:1385058 |
| Murase N et al. | Effect of FK 506 and antiproliferative agents for heart and liver xenotransplantation from hamster to rat. | 1993 | Transplant. Proc. | pmid:7679817 |
| Schreier MH et al. | Inhibition of T-cell signaling pathways by immunophilin drug complexes: are side effects inherent to immunosuppressive properties? | 1993 | Transplant. Proc. | pmid:7679818 |
| Kahan BD | Cyclosporine: the base for immunosuppressive therapy--present and future. | 1993 | Transplant. Proc. | pmid:7679819 |
| Starzl TE | FK 506 versus cyclosporine. | 1993 | Transplant. Proc. | pmid:7679820 |
| Todo S et al. | Intestinal transplantation in humans under FK 506. | 1993 | Transplant. Proc. | pmid:7680148 |
| Reyes J et al. | Nutritional management of intestinal transplant recipients. | 1993 | Transplant. Proc. | pmid:7680149 |
| Abu-Elmagd KM et al. | Monitoring and treatment of intestinal allograft rejection in humans. | 1993 | Transplant. Proc. | pmid:7680150 |
| McCauley J et al. | FK 506 in the management of nephrotic syndrome after renal transplantation. | 1993 | Transplant. Proc. | pmid:7680154 |
| Tsai M et al. | Activation of MAP kinases, pp90rsk and pp70-S6 kinases in mouse mast cells by signaling through the c-kit receptor tyrosine kinase or Fc epsilon RI: rapamycin inhibits activation of pp70-S6 kinase and proliferation in mouse mast cells. | 1993 | Eur. J. Immunol. | pmid:7504992 |
| Hendrickson BA et al. | Structural organization of the genes encoding human and murine FK506-binding protein (FKBP) 13 and comparison to FKBP1. | 1993 | Gene | pmid:7505249 |
| Lundemose AG et al. | Chlamydia trachomatis Mip-like protein has peptidyl-prolyl cis/trans isomerase activity that is inhibited by FK506 and rapamycin and is implicated in initiation of chlamydial infection. | 1993 | Mol. Microbiol. | pmid:7682281 |
| Wiesner RH et al. | Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection. | 1993 | Transplant. Proc. | pmid:7682352 |
| Deardon DJ et al. | Small bowel tonometry: a possible technique for detecting early small bowel allograft dysfunction. | 1993 | Transplant. Proc. | pmid:7505502 |
| Frank B et al. | Neurotoxicity of FK 506 in liver transplant recipients. | 1993 | Transplant. Proc. | pmid:7682355 |
| Klintmalm GB et al. | Rejection: FK 506 for rescue or maintenance. | 1993 | Transplant. Proc. | pmid:7682356 |
| Woodle ES et al. | Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection. | 1993 | Transplant. Proc. | pmid:7682358 |
| Tokunaga Y et al. | Living related liver transplantation across ABO blood groups with FK506 and OKT3. | 1993 | Transpl. Int. | pmid:7507676 |
| Winkler M et al. | Conversion from cyclosporin to FK 506 after liver transplantation. | 1993 | Transpl. Int. | pmid:7507677 |
| David M et al. | [Changes in cervix cytology in women with liver transplants treated with immunosuppressive therapy]. | 1993 | Zentralbl Gynakol | pmid:7692689 |
| Wallemacq PE and Reding R | FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects. | 1993 | Clin. Chem. | pmid:7693372 |
| Nakamura T et al. | Protein phosphatase type 2B (calcineurin)-mediated, FK506-sensitive regulation of intracellular ions in yeast is an important determinant for adaptation to high salt stress conditions. | 1993 | EMBO J. | pmid:7693452 |
| Higa A et al. | Attenuation of epithelial injury in acute experimental colitis by immunomodulators. | 1993 | Eur. J. Pharmacol. | pmid:7693488 |
| Takeda Y et al. | Stimulation of endothelin mRNA and secretion in human endothelial cells by FK 506. | 1993 | J. Cardiovasc. Pharmacol. | pmid:7509973 |
| Becker JW et al. | FK-506-binding protein: three-dimensional structure of the complex with the antagonist L-685,818. | 1993 | J. Biol. Chem. | pmid:7684380 |
| Dickey JB et al. | Periocular FK-506 delays allograft rejection in rat penetrating keratoplasty. | 1993 | Cornea | pmid:7684663 |
| Francavilla A et al. | Hepatic regeneration and growth factors. | 1993 | J Surg Oncol Suppl | pmid:7684910 |
| Connelly PR et al. | Probing hydration contributions to the thermodynamics of ligand binding by proteins. Enthalpy and heat capacity changes of tacrolimus and rapamycin binding to FK506 binding protein in D2O and H2O. | 1993 | Biochemistry | pmid:7684925 |
| Thomson AW et al. | FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh. | 1993 | Springer Semin. Immunopathol. | pmid:7686690 |
| Koga T et al. | Pulmonary infiltrates recovered by FK506 in a patient with Behçet's disease. | 1993 | Chest | pmid:7686837 |
| Nishi M et al. | Effects of the immunosuppressant FK506 on a penetrating keratoplasty rejection model in the rat. | 1993 | Invest. Ophthalmol. Vis. Sci. | pmid:7686893 |
| Odocha O et al. | Serum cholesterol levels in African Americans after renal transplantation under FK 506 immunosuppression. | 1993 | Transplant. Proc. | pmid:7689269 |
| McCauley J et al. | Renal transplantation under FK 506 in African-Americans: early experience. | 1993 | Transplant. Proc. | pmid:7689270 |
| Groth CG et al. | New immunosuppressive drugs in transplantation. | 1993 | Transplant. Proc. | pmid:7689274 |
| McMaster P and Buist L | FK 506 in transplantation. | 1993 | Transplant. Proc. | pmid:7689275 |
| Hacker J and Fischer G | Immunophilins: structure-function relationship and possible role in microbial pathogenicity. | 1993 | Mol. Microbiol. | pmid:7526121 |
| Whitington PF et al. | Orthotopic auxiliary liver transplantation for Crigler-Najjar syndrome type 1. | 1993 | Lancet | pmid:7690444 |
| Takahashi H and Iizuka H | Neither cyclosporin A nor FK506 affects adenylate cyclase responses of fetal rat keratinizing epidermal cells (FRSK cells) at concentrations that inhibit thymidine incorporation. | 1993 | J. Dermatol. Sci. | pmid:7511000 |